Semaglutide 7.2 mg: What the STEP UP Trial Actually Showed

STEP UP was a phase 3b randomized, double-blind, placebo-controlled trial designed to answer a single practical question: does more semaglutide produce more weight loss?

The current approved weight-management dose of semaglutide - sold as Wegovy - tops out at 2.4 mg once weekly. STEP UP tested 7.2 mg once weekly, roughly three times that amount, against both the 2.4 mg dose and placebo. More than 1,400 adults with obesity and without type 2 diabetes were randomized, and the trial ran for 72 weeks. Results were published in *The Lancet Diabetes & Endocrinology* in 2025 after being presented at the American Diabetes Association Scientific Sessions.

The logic behind the trial is straightforward. GLP-1 medications show a dose-response relationship - within limits, higher doses produce more weight loss. That pattern held across the original STEP programme and drove the design of tirzepatide's dose ladder too. Novo Nordisk wanted to know how much headroom was left above 2.4 mg, particularly as tirzepatide had begun outperforming semaglutide in head-to-head testing. In [SURMOUNT-5](/blog/tirzepatide-vs-semaglutide-surmount-5-head-to-head), tirzepatide produced 20.2% weight loss against semaglutide's 13.7% over 72 weeks.

A companion trial, STEP UP T2D, ran the same comparison in people who also have type 2 diabetes, where weight loss on GLP-1s is consistently smaller.

The design detail worth knowing: participants escalated to the 7.2 mg dose gradually over about 20 weeks rather than jumping straight there. That slow ramp matters, because tolerability at high doses depends heavily on how fast you get there.

About three percentage points more than on the standard dose. That is the honest headline.

At week 72, mean weight loss was:

• •18.7% with semaglutide 7.2 mg
• •15.6% with semaglutide 2.4 mg
• •3.9% with placebo

For a woman starting at 200 pounds, that translates to roughly 37 pounds on the higher dose versus 31 pounds on the standard one - a real difference of about 6 pounds, but not a transformation of the drug's profile.

The more striking finding sits in the tail of the distribution. 33.2% of participants on 7.2 mg lost 25% or more of their body weight, compared with 16.7% on 2.4 mg and none on placebo. Doubling the proportion of people reaching a quarter of their body weight lost is clinically meaningful, because that magnitude of loss starts to approach what bariatric surgery achieves.

You will also see the figure 20.7% quoted for this trial, which is not an error. Modern obesity trials report two estimands: the *treatment policy* estimate, which includes everyone regardless of whether they stopped the drug or started another one, and the *trial product* estimate, which models what happens if people stay on treatment as intended. The 18.7% figure is the treatment policy result - the more conservative and generally more realistic one. The 20.7% is the trial product result.

Both are legitimate. The lower number better reflects what happens in the real world, where people miss doses, pause during illness, and sometimes stop entirely.

Yes, but less dramatically than the tripled dose might suggest. The side-effect profile stayed recognisably the same shape - it just got somewhat more common.

The dominant adverse events at both doses were gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These occurred more often on 7.2 mg than on 2.4 mg, and the investigators characterised them as predominantly mild to moderate in severity and concentrated in the dose-escalation period rather than persisting through maintenance. This is the familiar GLP-1 pattern - symptoms cluster in the weeks after each step up, then settle.

Discontinuation because of side effects was higher on the top dose than on the standard one, which is what you would expect and is the practical ceiling on any dose-escalation strategy. A drug that works better but that fewer people can stay on does not necessarily deliver more benefit at the population level.

No new safety signal emerged. That is an important null result: the concern with pushing GLP-1 doses upward is not just tolerability but whether something qualitatively different appears - pancreatitis, gallbladder disease, or the kind of unexpected finding that ends a programme. STEP UP did not produce one.

If you already struggle with [nausea on your current dose](/blog/glp1-nausea-why-it-happens-and-how-to-ease-it), a higher dose is unlikely to be kinder. And if gut slowdown is your main issue, our guides to [constipation](/blog/glp1-constipation-why-it-happens-and-how-to-relieve-it) and hydration are worth reading before you consider escalating.

One under-discussed consequence of larger, faster weight loss: more of it can come from lean tissue. Protein intake and resistance training become more important as the dose climbs, not less.

Somewhat, but it does not close the gap. It narrows it.

The cleanest comparison remains SURMOUNT-5, the head-to-head trial in which tirzepatide 10 or 15 mg produced 20.2% weight loss against semaglutide 2.4 mg's 13.7% over 72 weeks (Aronne et al., *NEJM* 2025). Semaglutide at 7.2 mg reaching 18.7% in STEP UP brings it much closer to tirzepatide territory.

But cross-trial comparisons are genuinely unreliable. STEP UP and SURMOUNT-5 enrolled different populations, at different sites, in different years, with different baseline characteristics. The only way to know whether 7.2 mg semaglutide matches 15 mg tirzepatide is to test them against each other directly, and that trial has not been run.

What STEP UP does establish is that semaglutide's dose-response curve had not flattened at 2.4 mg. There was more efficacy available; the approved dose was simply not capturing it. Whether the additional 3 percentage points justify the extra side-effect burden and, presumably, extra cost is a judgement call rather than a scientific one.

The broader context is that the obesity drug field is moving quickly. Tirzepatide targets two receptors instead of one. Retatrutide targets three. Oral options like [orforglipron](/blog/orforglipron-foundayo-oral-glp1-pill-attain-results) are arriving. A higher-dose injectable semaglutide is an incremental step in a field taking larger ones.

For a patient, though, incremental is not nothing. Someone tolerating semaglutide well who has plateaued short of their goal may find a higher dose more appealing than switching molecules entirely.

Not as a routine prescription in most places, and not simply by asking.

A completed phase 3b trial is not the same as an approved product. Novo Nordisk would need to file for regulatory approval of the higher dose, and regulators would need to review the full data package - efficacy, safety, and manufacturing - before a 7.2 mg pen reaches pharmacies. That process typically takes a year or more from filing, and approval is never guaranteed.

In the meantime, a few things are worth knowing:

Do not try to improvise the dose. Combining pens or taking doses more frequently to reach 7.2 mg is unsafe, unstudied outside of a controlled trial, and can produce serious gastrointestinal effects. The trial's slow 20-week escalation was part of what made the dose tolerable.

Compounded versions are not a workaround. Compounded semaglutide at non-standard doses carries dosing-error risk and is not equivalent to a studied, approved product.

Other options exist for a stalled plateau. Switching to tirzepatide, addressing protein and resistance training, reviewing medications that promote weight gain, and checking thyroid function are all reasonable steps. Our guide to [breaking a GLP-1 plateau](/blog/glp1-weight-loss-plateau-why-it-stalls-and-what-to-do) covers the sequence.

Cost will matter. Higher doses generally mean higher prices, and coverage for weight-management GLP-1s is already inconsistent. If affordability is the binding constraint, [savings cards and cash pricing](/blog/glp1-savings-cards-cash-prices-lower-cost-2026) are more immediately useful than a dose that is not yet available.

The realistic summary: STEP UP is encouraging news about where semaglutide can go, not a change to what you can get this month.

The people most likely to gain from 7.2 mg are those who tolerate semaglutide well but respond to it modestly.

GLP-1 response varies widely between individuals. In every large trial, some participants lose 30% of their body weight and others lose almost nothing on the same dose. Roughly 10-15% of people are conventionally described as low responders - losing less than 5% of body weight after several months at a full dose. For that group, the question of whether they simply need more drug is a live and reasonable one, and STEP UP suggests the answer is sometimes yes.

The second group is people who lost well, plateaued, and remain far from a healthy weight. A plateau on a GLP-1 usually reflects a new equilibrium between appetite suppression and metabolic adaptation rather than the drug failing. Raising the dose can shift that equilibrium. Whether it should is a conversation about goals, side effects, and cost.

The people least likely to benefit are those already managing meaningful gastrointestinal symptoms, anyone struggling to eat enough protein, and people who have reached a weight they are content with. More weight loss is not automatically better. Losing 25% of your body weight has real consequences for bone density, muscle mass, and facial volume, and those consequences deserve planning rather than surprise - particularly for women going through menopause at the same time, where [bone loss is already accelerating](/blog/glp1-bone-density-menopause-protecting-your-bones).

If you are curious about how a higher dose might apply to you, the productive move is a conversation with your prescriber about your response so far, not a decision made in advance of one.